Incorrect password
evipedia.ai Suggest Edit

Niacin for Health & Longevity

Evidence Review created on 04/27/2026 using AI4L / Opus 4.7

Also known as: Nicotinic Acid, Vitamin B3, Niacinamide, Nicotinamide

Motivation

Niacin (vitamin B3) is an essential water-soluble nutrient that exists in two principal supplemental forms — nicotinic acid and nicotinamide (also called niacinamide). Both feed into the body’s pool of a central coenzyme required for hundreds of metabolic reactions, including those that generate cellular energy and repair DNA. Niacin holds a unique place in medical history: it cured pellagra (a deficiency disease causing skin rash, diarrhea, and dementia) in the 1930s and, decades later, became the first cholesterol-lowering therapy ever shown to reduce heart attacks.

The cardiovascular story has since become more complicated. When niacin is added to modern statin therapy, large outcome trials have not shown additional benefit, and recent research has identified a niacin breakdown product that itself may promote vascular inflammation. At the same time, the nicotinamide form has shown promise as a low-cost agent for reducing non-melanoma skin cancers and is being investigated for glaucoma neuroprotection.

This review examines the differing benefit and risk profiles of nicotinic acid and nicotinamide, the unresolved cardiovascular debate, and the emerging applications most relevant to a longevity-oriented strategy.

Benefits - Risks - Protocol - Conclusion

A curated selection of expert resources covering niacin biology, the cardiovascular debate, dermatologic applications, and practical considerations for longevity-oriented use.

  • The Straight Dope on Cholesterol – Part VII - Peter Attia

    An in-depth analysis of niacin’s lipid effects (HDL [high-density lipoprotein, the “good” cholesterol particle] elevation, triglyceride reduction) and the AIM-HIGH outcome trial that failed to show additional cardiovascular benefit when niacin was added to statin therapy, providing essential context for the modern cardiovascular debate.

  • How to Improve Skin Health & Appearance - Andrew Huberman

    An episode covering oral nicotinamide (typically 500 mg twice daily) for skin health and chemoprevention of non-melanoma skin cancers, situating niacinamide within a broader evidence-based skincare framework.

  • Niacin: Impact on Your Cardiovascular Health - William Davis

    A comprehensive overview of niacin’s effects on HDL, LDL (low-density lipoprotein, the “bad” cholesterol particle), triglycerides, and lipoprotein(a) (Lp(a), an LDL-like particle linked to atherosclerosis), drawing on the early outcome trials (Coronary Drug Project, HATS) that established its cardiovascular reputation, written for a longevity-oriented audience.

  • Niacin in Cardiovascular Disease: Recent Preclinical and Clinical Developments - Digby et al., 2012

    A narrative review covering niacin’s HDL-raising properties, the residual cardiovascular risk problem, and emerging anti-inflammatory effects through HCA2 (hydroxycarboxylic acid receptor 2, also called GPR109A, a receptor expressed on adipocytes and immune cells), situating niacin within the broader lipid-modifying landscape.

  • Influence of nicotinic acid on serum cholesterol in man - Altschul et al., 1955

    The original paper from Rudolf Altschul and colleagues demonstrating that gram-level doses of nicotinic acid lower serum cholesterol in humans, the foundational observation that launched niacin’s role as the first cholesterol-lowering therapy.

Rhonda Patrick has discussed high-dose niacin and heart disease in Q&A 58 (4/6/24), but the relevant content is behind a premium paywall and her dedicated topic pages center on NR (nicotinamide riboside) and NMN (nicotinamide mononucleotide) rather than niacin proper. Chris Kresser does not maintain a dedicated niacin article on chriskresser.com.

Grokipedia

Vitamin B3

A reference article covering vitamin B3 chemistry (nicotinic acid and nicotinamide), absorption and bioavailability, the role of tryptophan in endogenous niacin synthesis, dietary sources, the recommended dietary allowance (14–16 mg NE for adults), pellagra, and the contemporary debate around high-dose use for cardiovascular and longevity applications.

Examine

Niacin (Vitamin B3)

An evidence-graded supplement page summarizing niacin’s lipid effects, the three formulations (immediate-release, sustained-release, extended-release) and their distinct flushing and hepatotoxicity profiles, side effects, dose-response data, and a research breakdown organized by outcome.

ConsumerLab

Niacin / Niacinamide Reviews

A dedicated landing page collecting independent product reviews, top picks, warnings, and clinical updates for niacin and niacinamide supplements, including laboratory verification of label claims and notes on the differing tolerability of the immediate-release, sustained-release, and extended-release forms.

Systematic Reviews

A selection of recent systematic reviews and meta-analyses examining oral niacin and nicotinamide across cardiovascular, dermatologic, ophthalmologic, and metabolic endpoints in humans.

Mechanism of Action

Niacin is a generic name for two related forms of vitamin B3 — nicotinic acid and nicotinamide — that share a common ultimate role: replenishing the cellular pool of NAD+ (nicotinamide adenine dinucleotide, a coenzyme central to energy production, DNA repair, and metabolic regulation) and its phosphorylated form NADP+. The two forms differ markedly in their secondary pharmacology, which explains their very different clinical profiles.

Lipid-modifying mechanism (nicotinic acid only):

  • Nicotinic acid is a high-affinity ligand for HCA2 (hydroxycarboxylic acid receptor 2, also called GPR109A, a receptor expressed on adipocytes and immune cells). Engagement of this receptor on fat cells inhibits lipolysis (the breakdown of stored fat to free fatty acids), reducing the substrate available to the liver for VLDL (very-low-density lipoprotein) production
  • Reduced VLDL output translates into lower triglycerides, lower LDL (low-density lipoprotein, the “bad” cholesterol particle), and modest elevation of HDL (high-density lipoprotein, the “good” cholesterol particle)
  • Nicotinic acid also reduces lipoprotein(a) — Lp(a), an LDL-like particle linked to atherosclerosis — by 20–30% at gram-level doses, an effect that is unique among the older lipid-modifying agents
  • Nicotinic acid binding to HCA2 on skin Langerhans cells and dermal blood vessels triggers prostaglandin D2 release, which causes the characteristic cutaneous flushing

NAD+ replenishment mechanism (both forms):

  • Both nicotinic acid (via the Preiss-Handler pathway) and nicotinamide (via the salvage pathway) are converted to NAD+ inside cells
  • NAD+ is a required co-substrate for sirtuins (SIRT1-7, a family of NAD+-dependent enzymes regulating DNA repair, metabolic homeostasis, and stress resistance), PARPs (poly-ADP-ribose polymerases, NAD+-consuming enzymes critical for DNA strand-break repair), and CD38 (a NAD+-degrading enzyme whose expression rises with age)
  • In retinal ganglion cells, NAD+ supports mitochondrial bioenergetics, which is the basis for ongoing trials of nicotinamide for glaucoma neuroprotection
  • In keratinocytes, NAD+ supports DNA repair after UV damage, supporting the chemopreventive rationale for nicotinamide in non-melanoma skin cancer

The 4PY pathway and cardiovascular signal:

A 2024 multi-cohort study (Ferrell et al., 2024) identified two terminal niacin metabolites — N1-methyl-2-pyridone-5-carboxamide (2PY) and N1-methyl-4-pyridone-3-carboxamide (4PY) — as independent predictors of major adverse cardiovascular events. Mechanistic experiments showed that 4PY (but not 2PY) induces VCAM-1 (vascular cell adhesion molecule 1, an endothelial protein that recruits inflammatory cells) and promotes leukocyte adhesion to the vascular wall. This mechanism is consumed by methyl groups via methylation of nicotinamide and is therefore particularly relevant at supraphysiologic doses.

Key pharmacological properties (nicotinic acid):

  • Half-life: Immediate-release nicotinic acid has a plasma half-life of about 20–45 minutes; extended-release formulations are designed to deliver gradual exposure over 8–12 hours to mitigate flushing
  • Selectivity: Engages HCA2 with high affinity for lipid effects; converts to NAD+ via the Preiss-Handler route
  • Tissue distribution: Wide; concentrates in liver, where most lipid-modifying effects originate
  • Metabolism: Hepatic conjugation (low-dose, low-flush pathway) and amidation (high-dose, hepatotoxicity-associated pathway); methylation produces 2PY and 4PY; renal excretion of metabolites

Key pharmacological properties (nicotinamide):

  • Half-life: Plasma half-life of approximately 4 hours; chronic dosing produces NAD+ elevation that persists across days
  • Selectivity: Does not engage HCA2 (no flushing, no lipid effects); enters NAD+ salvage pathway directly
  • Tissue distribution: Wide; crosses the blood-brain barrier
  • Metabolism: Methylation to N1-methylnicotinamide and downstream conversion to 2PY/4PY; renal excretion

Historical Context & Evolution

Niacin’s medical history is exceptional in spanning a fatal vitamin deficiency, the first proven cholesterol-lowering therapy, a major modern cardiovascular reversal, and a contemporary dermatologic resurgence.

In the early twentieth century, pellagra — a disease characterized by dermatitis, diarrhea, dementia, and death — was endemic in the American South, killing thousands annually. Joseph Goldberger demonstrated in 1914–1929 that pellagra was a dietary deficiency rather than an infectious disease. In 1937, Conrad Elvehjem and colleagues at the University of Wisconsin identified the missing factor as nicotinic acid, and US flour fortification with niacin from 1938 onward effectively eliminated endemic pellagra.

In 1955, Rudolf Altschul and Abram Hoffer in Saskatchewan reported that gram-level doses of nicotinic acid (well above the nutritional requirement) lowered serum cholesterol in humans — a finding that launched niacin as a cholesterol-modifying therapy. The Coronary Drug Project (1975) found that niacin reduced recurrent myocardial infarction in men with prior heart attack, and a 15-year follow-up reported a mortality benefit, making niacin the first cholesterol-lowering therapy with a documented survival advantage. The HDL Atherosclerosis Treatment Study (HATS, 2001) added angiographic and event-rate evidence, and niacin became a mainstay of integrative and conventional cardiovascular practice.

The picture inverted in the modern statin era. AIM-HIGH (2011, sponsored by NHLBI with study drug supplied by Abbott Laboratories — manufacturer of the niacin product Niaspan, which represents a direct financial interest in the trial outcome) randomized over 3,000 statin-treated patients with low HDL to extended-release niacin or placebo and was halted early for futility — niacin further raised HDL and lowered triglycerides but did not reduce cardiovascular events. HPS2-THRIVE (2014, sponsored by Merck — manufacturer of the niacin–laropiprant combination Tredaptive, also a direct financial interest) tested niacin plus laropiprant (an anti-flushing agent) in over 25,000 patients on simvastatin and likewise showed no event reduction, with increased rates of bleeding, infection, gastrointestinal events, and new-onset diabetes in the niacin arm. These trials shifted mainstream cardiology away from routine add-on niacin. Mainstream guideline downgrading of niacin coincides with the commercial rise of statins and PCSK9 inhibitors; institutional payers have a structural financial incentive to favor patented, high-margin therapies (statins until generic, PCSK9 inhibitors thereafter) over inexpensive generic niacin, a potential source of bias in guideline formation and ongoing research funding that should be considered alongside the trial evidence itself.

Two further developments are still reshaping the field. The 2024 Ferrell et al. study identifying the niacin terminal metabolite 4PY as a driver of vascular inflammation provided a possible mechanistic explanation for why elevating HDL with niacin might not translate into clinical benefit. In parallel, the 2015 ONTRAC trial demonstrated a 23% reduction in non-melanoma skin cancers with oral nicotinamide 500 mg twice daily, opening a dermatologic chemoprevention indication that — while subsequently nuanced by larger meta-analyses and mixed real-world data through 2025–2026 — remains an active area of clinical use. Glaucoma neuroprotection trials are now in Phase 3.

The current scientific dialogue thus carries forward both legacies: niacin remains an evidence-supported lipid-modifier (especially for Lp(a) and triglycerides), but its routine cardiovascular benefit on top of statins is unsettled, while nicotinamide is finding new applications outside the lipid space.

Expected Benefits

A dedicated search for niacin and nicotinamide’s benefit profile was performed using PubMed, ClinicalTrials.gov, expert sources, and product reference materials before writing this section.

High 🟩 🟩 🟩

Lipoprotein(a) Reduction

Nicotinic acid (1.5–3 g/day) is one of the few oral therapies — alongside PCSK9 inhibitors (proprotein convertase subtilisin/kexin type 9 inhibitors, a class of injectable lipid-lowering drugs) — that lowers Lp(a) (lipoprotein(a), an LDL-like particle linked to atherosclerosis), an outcome confirmed in the Xie et al., 2025 meta-analysis of lipid-lowering therapies. For longevity-oriented adults with elevated Lp(a) and limited access to PCSK9 inhibitors, niacin is one of the most cost-effective options to reduce this independent atherosclerotic risk factor.

Magnitude: Approximately 20–30% reduction in Lp(a) at doses of 1.5–3 g/day of extended-release nicotinic acid.

Triglyceride Reduction and HDL Elevation

Nicotinic acid is a potent triglyceride-lowering and HDL-raising agent, with effects established across decades of trials and confirmed in modern meta-analyses including Saboori et al., 2024 (apoA1 elevation, apoB reduction). The lipid effects are dose-dependent and most pronounced with extended-release formulations at gram-level doses.

Magnitude: Triglyceride reduction of 20–50%, HDL elevation of 15–35%, and LDL reduction of 5–25% at doses of 1–2 g/day.

Pellagra Treatment and Prevention

Niacin is curative for pellagra at modest oral doses (50–500 mg/day of nicotinic acid or nicotinamide, depending on severity). This is the original and most secure indication, with effectively complete reversal of dermatitis, diarrhea, and neurological symptoms when treated early. While pellagra is rare in industrialized countries thanks to flour fortification, it remains relevant for adults with malabsorption, alcohol use disorder, isoniazid use, or carcinoid syndrome (a rare endocrine disorder in which serotonin-secreting tumors divert tryptophan away from niacin synthesis).

Magnitude: Symptomatic resolution of pellagra typically within days to weeks of niacin replacement.

Medium 🟩 🟩

Reduced Non-Melanoma Skin Cancer Incidence ⚠️ Conflicted

The ONTRAC Phase 3 trial (Chen et al., 2015) showed that oral nicotinamide 500 mg twice daily reduced new non-melanoma skin cancers (basal cell carcinoma plus squamous cell carcinoma) by 23% over 12 months in immunocompetent patients with a history of skin cancer, with 11–20% reductions in actinic keratoses (precancerous skin lesions). However, the Tosti et al., 2023 meta-analysis pooling four trials, including transplant populations, found no statistically significant overall reduction. A 2025 retrospective Veterans Affairs cohort (Breglio et al., 2025) reported a 14% overall risk reduction (54% when initiated after the first skin cancer), but a 2026 critical appraisal (Tan & Williams, 2026) flagged immortal-time bias and confounding. The strongest evidence remains in immunocompetent individuals with prior non-melanoma skin cancer.

Magnitude: Approximately 23% reduction in non-melanoma skin cancers in ONTRAC; 14% overall and 22% for cutaneous squamous cell carcinoma in the 2025 VA cohort; null result in pooled meta-analysis.

Reduced Inflammation Markers

The Rad et al., 2024 meta-analysis of 15 RCTs found that niacin reduces CRP (standardized mean difference −0.88) and TNF-α, with effects most pronounced at doses ≤1,000 mg/day, durations ≤24 weeks, and elevated baseline CRP (>3 mg/L). The Lei et al., 2023 meta-analysis of 29 NAD+-precursor RCTs likewise showed CRP reduction of approximately 0.93 mg/L. These effects appear distinct from niacin’s lipid mechanism and may contribute to its broader cardiovascular and metabolic profile.

Magnitude: CRP reduction of approximately 0.9 mg/L; significant TNF-α reduction; effect strongest in those with elevated baseline inflammation.

Modest Blood Pressure Reduction

The Lei et al., 2023 meta-analysis reported that NAD+ precursor supplementation (predominantly nicotinic acid) reduced systolic blood pressure by approximately 2.5 mmHg and diastolic blood pressure by approximately 2.2 mmHg, with the largest effects at doses ≥2 g and durations >12 weeks. The mechanism is uncertain and may involve nicotinic-acid–mediated vasodilation or sirtuin-mediated endothelial effects.

Magnitude: Approximately 2.5 mmHg systolic and 2.2 mmHg diastolic reduction.

Low 🟩

Skin Quality and Anti-Aging Effects

Topical and oral niacinamide reduce hyperpigmentation, sebum production, and trans-epidermal water loss, and improve skin barrier function via increased ceramide synthesis. Evidence is largely from small dermatologic RCTs and product-development studies. Practitioners commonly recommend oral niacinamide 500 mg twice daily for skin-quality improvement, with effects appearing over 3–6 months.

Magnitude: Modest improvements in skin moisture, redness, and pigmentation in dermatologic trials; effect sizes generally small.

Glaucoma Neuroprotection

Pilot trials and the Nicola et al., 2024 meta-analysis of dietary intake studies suggest that niacin/nicotinamide may slow retinal ganglion cell degeneration in glaucoma. The Phase 3 NAMinG trial (NCT05405868) and the multi-arm precursor comparison (NCT06991712) are expected to clarify whether oral nicotinamide preserves visual function in open-angle glaucoma.

Magnitude: Approximately 34% lower glaucoma prevalence in those with high dietary niacin intake (case-control data); intervention-trial magnitude pending.

Cardiovascular Event Reduction in Specific Subgroups ⚠️ Conflicted

The Coronary Drug Project (1975) and 15-year follow-up showed that nicotinic acid reduced recurrent myocardial infarction and all-cause mortality in men with prior heart attack, predating routine statin therapy. HATS (2001) showed angiographic and event benefit in patients with low HDL. By contrast, AIM-HIGH (2011) and HPS2-THRIVE (2014), conducted in patients on intensive statin therapy, showed no event reduction with add-on niacin. The Salem et al., 2026 TriNetX cohort in dermatology patients on niacinamide reported reductions in ST-elevation myocardial infarction, peripheral vascular disease, and cardiac arrest, raising questions about whether nicotinamide-only exposure (without nicotinic acid’s full metabolite spectrum) might preserve cardiovascular benefit. The benefit signal in patients not on background statins, in those with elevated Lp(a), or in those with elevated triglycerides is not clearly contradicted by the modern null trials.

Magnitude: 11% all-cause mortality reduction at 15-year follow-up in the Coronary Drug Project; null in AIM-HIGH and HPS2-THRIVE on top of statins.

Reduced Adipokine Dysregulation

The Rad et al., 2024 meta-analysis showed that niacin elevates adiponectin (an insulin-sensitizing adipokine, generally favorable) but also raises leptin (an appetite-regulating adipokine, mixed implications). The Baichuan et al., 2023 meta-regression of 22 NAD+-precursor trial arms found a small reduction in BMI (body mass index, weight in kg divided by height in meters squared) of about 0.2 kg/m².

Magnitude: BMI reduction of approximately 0.2 kg/m²; modest favorable effects on adiponectin.

Speculative 🟨

NAD+-Mediated Healthspan Effects

By replenishing NAD+, both nicotinic acid and nicotinamide could in principle support sirtuin-driven healthspan benefits, mitochondrial function, and DNA repair. In humans, the most consistent NAD+-precursor benefits have been established for nicotinamide riboside and NMN (covered in their own reviews); whether plain nicotinic acid or nicotinamide produce comparable healthspan effects in healthy aging populations has not been tested in dedicated trials.

Cognitive and Neurodegenerative Benefits

Mechanistic data and small case series have suggested possible benefits of niacin/nicotinamide in Parkinson’s disease and mild cognitive impairment, primarily via NAD+ replenishment in vulnerable neurons. Definitive human trials are limited and most NAD+-cognition data come from nicotinamide riboside and NMN rather than plain nicotinamide.

Pre-Diabetes Modulation via Gut-Targeted Niacin

A novel ileal-release nicotinic acid formulation is being tested in the Phase 2 CONCEPT trial (NCT07286747) for prevention of progression from prediabetes (impaired glucose tolerance) to type 2 diabetes via gut-microbiome modulation. Mechanism and dose are deliberately designed to bypass the systemic metabolite pathway implicated in cardiovascular signal.

Benefit-Modifying Factors

  • Form of niacin: Nicotinic acid drives lipid effects (HDL, triglycerides, Lp(a)) and produces flushing; nicotinamide does not engage HCA2 and is the preferred form for skin, glaucoma, and NAD+ applications. Choosing the wrong form for the target outcome is the single most common clinical mistake.

  • Baseline lipid profile: Greatest absolute lipid benefits accrue to those with the most abnormal baseline values — high triglycerides, low HDL, or elevated Lp(a). Adults already on optimized statin therapy with low LDL (low-density lipoprotein) and triglycerides see smaller incremental benefit, consistent with the AIM-HIGH and HPS2-THRIVE null results.

  • Baseline inflammation: The CRP-lowering effect of niacin is most pronounced in those with hsCRP (high-sensitivity C-reactive protein) >3 mg/L; those with low baseline inflammation see little change.

  • Sex-based differences: Women may experience more pronounced flushing and skin-related side effects with nicotinic acid, although clinically meaningful efficacy differences are not consistently documented. Several lipid trials have been male-predominant, limiting sex-stratified efficacy estimates.

  • Pre-existing health conditions: Adults with prior non-melanoma skin cancer are the population in which the strongest nicotinamide chemoprevention signal has been observed (ONTRAC). Adults with elevated Lp(a) or atherogenic dyslipidemia derive more benefit from nicotinic acid than those with optimized lipid panels.

  • Age-related considerations: Most positive niacin lipid trials have been conducted in middle-aged and older adults. ONTRAC’s average participant age was 66. Older adults are more likely to benefit from skin-cancer chemoprevention applications, while modern statin co-therapy diminishes incremental cardiovascular benefit.

  • Genetic polymorphisms: Variants in HCA2 may modulate flushing intensity. Variants affecting one-carbon metabolism (MTHFR, methylenetetrahydrofolate reductase, an enzyme central to folate metabolism) may influence the methylation of nicotinamide to 2PY/4PY and could in principle affect both efficacy and the cardiovascular metabolite signal.

Potential Risks & Side Effects

A dedicated search for niacin and nicotinamide’s side effect profile was performed using PubMed, ClinicalTrials.gov safety reports, drugs.com, expert sources, and Examine.com before writing this section. The 2025 Young & Gazzard overview of reviews is the most comprehensive recent summary.

High 🟥 🟥 🟥

Cutaneous Flushing (Nicotinic Acid)

The hallmark adverse effect of nicotinic acid is intense skin flushing — sudden facial and upper-body redness, warmth, tingling, and itching — caused by HCA2-mediated prostaglandin D2 release. Flushing affects the great majority of users on immediate-release nicotinic acid at gram-level doses, is the leading cause of treatment discontinuation, and is one of the principal reasons extended-release formulations were developed. Flushing tends to attenuate over 4–8 weeks of continued dosing and can be partially mitigated by aspirin pretreatment, gradual titration, and taking with food.

Magnitude: Approximately 70–90% incidence with immediate-release nicotinic acid; 30–50% with extended-release; low with nicotinamide.

Hepatotoxicity (Sustained-Release Nicotinic Acid)

Sustained-release nicotinic acid formulations have been clearly associated with dose-dependent hepatotoxicity, including elevations in liver enzymes (ALT, alanine aminotransferase; AST, aspartate aminotransferase — both liver enzymes) and rare cases of fulminant hepatic failure, particularly at doses ≥2 g/day. Immediate-release and extended-release prescription formulations have a substantially lower hepatotoxicity profile but still warrant liver enzyme monitoring at gram-level doses.

Magnitude: Hepatotoxicity rates of approximately 5–10% with sustained-release formulations at ≥2 g/day; substantially lower with extended-release; rare with nicotinamide at doses <1,500 mg/day.

Medium 🟥 🟥

Increased Cardiovascular Event Risk via 4PY ⚠️ Conflicted

Ferrell et al., 2024 reported that elevated serum levels of the niacin terminal metabolites 2PY and 4PY are associated with significantly increased 3-year major adverse cardiovascular event risk (adjusted hazard ratios approximately 1.6–2.0), and that 4PY drives vascular inflammation through VCAM-1 induction in mice. This finding offers a possible mechanistic explanation for the lack of cardiovascular benefit in AIM-HIGH and HPS2-THRIVE despite favorable lipid changes. The Salem et al., 2026 TriNetX cohort in dermatology patients on niacinamide reported the opposite — reduced major cardiovascular events — leaving the population-level cardiovascular implications of the 4PY pathway unresolved.

Magnitude: Approximately 1.6–2.0 fold increase in 3-year MACE (major adverse cardiovascular events: heart attack, stroke, cardiovascular death) risk associated with high 2PY/4PY serum levels; offset or absent in some real-world cohorts; mechanism best established at supraphysiologic niacin exposures.

Hyperuricemia and Gout Flare (Nicotinic Acid)

Nicotinic acid impairs uric acid excretion and can precipitate gout flares in susceptible individuals. The effect is dose-dependent and was documented as an excess adverse event in HPS2-THRIVE.

Magnitude: Modest increase in serum uric acid (approximately 0.5–1 mg/dL); gout flare incidence elevated by 30–50% in trials.

Hyperglycemia and New-Onset Diabetes (Nicotinic Acid)

Nicotinic acid causes a measurable rise in fasting glucose and HbA1c (glycated hemoglobin, a marker of long-term blood sugar control), and was associated with a statistically significant increase in new-onset diabetes in HPS2-THRIVE (approximately 1.3 fold). The mechanism is thought to involve hepatic insulin resistance via altered free fatty acid flux.

Magnitude: HbA1c elevation of approximately 0.1–0.3 percentage points; approximately 30% relative increase in new-onset diabetes in HPS2-THRIVE.

Low 🟥

Gastrointestinal Symptoms

Both forms of niacin can cause nausea, dyspepsia, abdominal discomfort, and diarrhea, particularly at gram-level doses and in the first weeks of treatment. Symptoms typically improve when the supplement is taken with food and when the dose is escalated gradually.

Magnitude: GI (gastrointestinal, relating to the stomach and intestines) symptom incidence of approximately 10–20% at gram-level doses; lower at sub-gram doses.

Bleeding and Infection (Nicotinic Acid)

HPS2-THRIVE reported a small but statistically significant increase in serious bleeding events and infection in the niacin-laropiprant arm. The mechanism for the bleeding signal is uncertain; the infection signal may relate to skin disruption from flushing and scratching or to immune-modulatory effects.

Magnitude: Approximately 1.4 fold increase in serious bleeding and approximately 1.2 fold increase in serious infection in HPS2-THRIVE.

Skin Rash and Pruritus

Beyond classic flushing, both nicotinic acid and nicotinamide can cause non-flush skin rashes, dryness, and itching. The 2025 Young & Gazzard overview identified these as commonly reported adverse events across multiple reviews.

Magnitude: Not quantified in available studies.

Macular Edema (Nicotinic Acid)

Rare cases of cystoid macular edema (fluid accumulation in the macula of the retina) have been reported with high-dose nicotinic acid (typically >1.5 g/day), generally reversible upon discontinuation.

Magnitude: Not quantified in available studies.

Speculative 🟨

Long-Term Safety of Sustained High-Dose Nicotinamide

Most randomized trials of high-dose oral nicotinamide (≥1 g/day) have run 12 months or less. Multi-year safety data — including effects on cancer incidence, cardiovascular outcomes, and methylation reserves — are limited. The 4PY signal makes this gap more salient for indefinite longevity-oriented use.

Methylation Burden

Both nicotinic acid and nicotinamide consume methyl groups during their disposal pathways, potentially stressing one-carbon metabolism in individuals with low folate, B12, or betaine status, or with MTHFR variants. Direct human evidence of clinically meaningful methylation depletion at typical doses is lacking.

Niacinamide and Tumor Microenvironment

By analogy to the preclinical cancer-promotion concerns raised for nicotinamide riboside in some breast-cancer mouse models, theoretical questions exist about whether sustained nicotinamide elevates NAD+ in pre-existing tumors. Direct human evidence is absent and the strongest current data (ONTRAC, VA cohort) suggest net cancer benefit in the skin-cancer setting.

Risk-Modifying Factors

  • Form of niacin: Nicotinic acid drives the flushing, lipid-effect, hepatotoxicity, and HCA2-mediated risks. Nicotinamide is generally better tolerated, with the principal residual concerns being long-term high-dose effects, methylation burden, and the 4PY signal at high exposures.

  • Genetic polymorphisms: Variants affecting one-carbon metabolism (MTHFR), HCA2 (GPR109A) signaling, and NAD+ catabolism (CD38) may modulate side-effect intensity and 4PY production. Pharmacogenomic guidance is not yet clinical standard.

  • Baseline biomarker levels: Elevated baseline liver enzymes (ALT, AST), uric acid, fasting glucose, or HbA1c, and reduced eGFR (estimated glomerular filtration rate, a kidney-function index) all warrant more careful monitoring on niacin. Adults with elevated baseline 2PY/4PY may, in principle, be at higher cardiovascular risk from supraphysiologic niacin exposures.

  • Sex-based differences: Women may experience more pronounced flushing on nicotinic acid; clinically meaningful sex-stratified safety differences are otherwise limited.

  • Pre-existing health conditions: Active liver disease, gout, type 2 diabetes, peptic ulcer disease, and atrial fibrillation (an irregular heart rhythm originating in the upper chambers of the heart) (in older AIM-HIGH analyses) all alter the niacin risk profile. Adults on intensive statin therapy obtain little incremental benefit but retain the side-effect burden of niacin.

  • Age-related considerations: Older adults (>65) have reduced renal and hepatic clearance, higher baseline rates of subclinical liver and kidney impairment, and a higher likelihood of polypharmacy interactions. Conversely, the chemopreventive skin-cancer benefit of nicotinamide is most relevant in this age group.

Key Interactions & Contraindications

Prescription drug interactions:

  • HMG-CoA reductase inhibitors (statins such as atorvastatin, rosuvastatin, simvastatin): Combination is associated with an increased risk of myopathy (muscle pain and weakness) and rhabdomyolysis (severe muscle breakdown), particularly with simvastatin doses >40 mg. Severity: caution. Mitigating action: avoid high-dose simvastatin combinations, monitor creatine kinase if muscle symptoms develop.
  • Anticoagulants (warfarin, apixaban, rivaroxaban): Theoretical and observed (HPS2-THRIVE) increase in bleeding risk. Severity: caution and monitor. Mitigating action: monitor INR (international normalized ratio, a coagulation index) closely on warfarin; review bleeding history before starting.
  • Antihypertensive medications (ACE inhibitors [angiotensin-converting enzyme inhibitors, drugs that relax blood vessels] such as lisinopril; ARBs [angiotensin receptor blockers, an alternative class that also relaxes blood vessels] such as losartan; alpha-blockers [drugs that relax vascular smooth muscle by blocking adrenergic receptors] such as doxazosin; calcium channel blockers [drugs that relax blood vessels by blocking calcium entry into smooth muscle] such as amlodipine): Possible additive vasodilation and hypotension, particularly during the flushing window. Severity: caution. Mitigating action: monitor blood pressure during initiation and titration.
  • Diabetes medications (insulin, metformin, sulfonylureas such as glipizide, GLP-1 [glucagon-like peptide 1, a gut hormone] receptor agonists such as semaglutide): Niacin may worsen glycemic control; HbA1c should be monitored. Severity: caution and monitor. Mitigating action: increase glucose monitoring during the first 8–12 weeks; adjust antidiabetic regimen as needed.
  • Carbamazepine (an anticonvulsant): Nicotinamide may inhibit hepatic metabolism of carbamazepine, increasing serum levels. Severity: caution. Mitigating action: monitor carbamazepine levels.
  • Allopurinol and uricosurics: Niacin counteracts uric acid lowering and may precipitate gout. Severity: caution. Mitigating action: optimize gout therapy before niacin initiation.

Over-the-counter medication interactions:

  • Aspirin (acetylsalicylic acid): 325 mg taken 30 minutes before niacin reduces flushing intensity. Severity: generally favorable. Clinical consequence: cumulative bleeding risk in those on chronic aspirin or anticoagulants. Mitigating action: do not add aspirin solely for flushing if already on antiplatelet therapy.
  • NSAIDs (non-steroidal anti-inflammatory drugs such as ibuprofen, naproxen): Similar to aspirin — reduce flushing but compound bleeding and renal effects. Severity: caution and monitor. Mitigating action: minimize chronic combined use.
  • Alcohol: Worsens flushing and hepatotoxicity. Severity: caution. Mitigating action: avoid alcohol within 4 hours of niacin doses; limit chronic intake.

Supplement interactions:

  • Other NAD+ precursors (nicotinamide riboside, NMN): Additive NAD+ pathway loading and methylation burden. Severity: caution. Clinical consequence: potential excess methylation demand and 4PY production. Mitigating action: avoid stacking maximal doses of multiple NAD+ precursors; consider cumulative niacin equivalents.
  • Methyl donors (folate, B12, choline, betaine, SAMe): May offset methylation burden of high-dose niacin; generally favorable. Severity: monitor. Clinical consequence: high methyl-donor intake may modestly raise blood pressure in salt-sensitive individuals. Mitigating action: maintain adequate but not excessive intake.
  • CoQ10 (coenzyme Q10, an antioxidant essential for mitochondrial function): Often paired with niacin in cardiovascular protocols. Severity: monitor (no known harm). Clinical consequence: potentially favorable; not formally tested. Mitigating action: none specifically.
  • Quercetin and apigenin (flavonoid CD38 inhibitors): Potentiate NAD+-precursor effects. Severity: monitor. Clinical consequence: amplified NAD+ pathway activity of unquantified clinical magnitude.
  • Red yeast rice and berberine (alternative lipid-modifiers): Additive lipid lowering. Severity: monitor. Clinical consequence: cumulative dose-response benefits and risks. Mitigating action: monitor lipid panel and liver enzymes.

Other intervention interactions:

  • Intermittent fasting and ketogenic diets: Both raise endogenous NAD+; combined with niacin, the cumulative metabolic effect is unstudied. Severity: monitor. Mitigating action: avoid initiating high-dose niacin during prolonged fasts.

Populations who should avoid or defer niacin:

  • Adults with active liver disease, including unexplained transaminase elevation (a rise in liver enzymes such as ALT and AST) >3× upper limit of normal
  • Adults with active peptic ulcer disease
  • Adults with active gout or recurrent gout flares without optimized therapy
  • Adults with poorly controlled type 2 diabetes (HbA1c >9%) without endocrinology guidance
  • Adults with advanced chronic kidney disease (eGFR <30 mL/min/1.73m², CKD or chronic kidney disease, Stage 4 or 5) without physician oversight
  • Pregnant or breastfeeding women on doses above the RDA (recommended dietary allowance, 14–18 mg/day) without medical guidance
  • Adults with arterial hypotension or recent stroke without physician oversight (flushing-related hypotension risk)
  • Children and adolescents on supplemental doses above the RDA without medical guidance

Risk Mitigation Strategies

  • Match the form to the goal: Use nicotinic acid (immediate-release or extended-release) when targeting Lp(a), triglycerides, or HDL; use nicotinamide when targeting skin-cancer chemoprevention, glaucoma neuroprotection, or NAD+ replenishment without lipid effects. This avoids unnecessary flushing, hepatotoxicity, and HCA2-driven side effects.

  • Low starting dose with gradual titration (nicotinic acid): Begin at 250–500 mg/day and increase by 250–500 mg every 2–4 weeks to the target dose (typically 1,000–2,000 mg/day for lipid effects). This mitigates flushing intensity, GI symptoms, and the spike in glucose or uric acid.

  • Aspirin pretreatment for flushing: 325 mg of aspirin taken 30 minutes before nicotinic acid substantially reduces flushing intensity. Use only in adults without bleeding contraindications and only for flushing, not as routine antiplatelet therapy.

  • Take with food, in the evening: Nicotinic acid taken with a low-fat snack at bedtime reduces flushing impact on daily activities; nicotinamide can be taken at any time but is often paired with breakfast to align with circadian NAD+ biology.

  • Avoid sustained-release nicotinic acid: Sustained-release (12+ hour, often labeled “no-flush” inositol hexanicotinate or specific brand designs) formulations have a substantially higher hepatotoxicity rate than immediate-release or prescription extended-release. Immediate-release at gram-level doses or prescription extended-release (Niaspan) is preferred; over-the-counter “no-flush” niacin is generally inactive on lipids.

  • Baseline and follow-up labs: Obtain ALT, AST, fasting glucose, HbA1c, uric acid, lipid panel, and creatinine before starting; repeat at 6–12 weeks, then every 6 months. This supports early detection of liver, glucose, kidney, and uric-acid effects.

  • Cap nicotinamide at 1,500 mg/day for routine use: The 2025 Young & Gazzard overview identified 1,500 mg/day of nicotinamide as a generally safe ceiling not requiring routine clinical monitoring; doses ≥3 g/day require monitoring. This addresses theoretical methylation burden and the 4PY pathway.

  • Support methylation status: Maintain adequate folate, B12, betaine, and choline intake (through diet or a comprehensive B-complex), particularly when using gram-level nicotinic acid or nicotinamide chronically. This offsets the theoretical methylation demand and 2PY/4PY production.

  • Defer niacin around active or recent cancer treatment: Although the strongest signal for nicotinamide skin-cancer chemoprevention is favorable, hold high-dose nicotinic acid or nicotinamide in adults with active solid tumors and discuss with oncology — particularly during PARP-inhibitor (poly-ADP-ribose polymerase inhibitor, a class of cancer drugs) therapy, where elevated NAD+ may counteract treatment.

  • Monitor for flushing tolerance and infection: Flushing typically attenuates over 4–8 weeks; persistent severe flushing should prompt dose reduction. Skin breakdown from chronic flushing-and-scratching may explain the modest infection signal in HPS2-THRIVE — keep skin moisturized.

Therapeutic Protocol

The most commonly used niacin protocols differ by goal and form. Within the longevity and lipid communities, competing therapeutic stances exist: lipidologists led by Tom Dayspring continue to use nicotinic acid for elevated Lp(a) and atherogenic dyslipidemia where modern alternatives are unavailable, while Peter Attia, MD, and other modern preventive cardiologists generally do not recommend routine niacin add-on to statins given the AIM-HIGH and HPS2-THRIVE null results and the 4PY signal. Dermatology practice (including Andrew Huberman’s discussions) supports oral nicotinamide 500 mg twice daily for skin-quality and chemoprevention applications.

  • For elevated Lp(a) or atherogenic dyslipidemia (nicotinic acid): Extended-release (Niaspan or equivalent) starting at 500 mg at bedtime for 4 weeks, increasing by 500 mg every 4 weeks to a target of 1,000–2,000 mg/day. This dose is the lowest typically needed to produce a 20–30% Lp(a) reduction.

  • For skin-cancer chemoprevention (nicotinamide): 500 mg twice daily of oral nicotinamide is the dose used in ONTRAC and most positive cohort data. Continuous use is required as benefit reverses upon discontinuation.

  • For skin-quality applications (nicotinamide): 500 mg twice daily oral, typically with topical niacinamide-containing skincare for additive effect. Effects emerge over 3–6 months.

  • For pellagra treatment: 50–500 mg/day of nicotinic acid or nicotinamide for 1–4 weeks until symptoms resolve, then maintenance via diet or a multivitamin.

  • For NAD+ replenishment as a longevity strategy: Plain niacin and nicotinamide are less commonly used than nicotinamide riboside or NMN; if used, doses are typically 100–500 mg/day of nicotinamide. Nicotinic acid in this role brings lipid effects and flushing as side considerations.

  • Best time of day: Nicotinic acid is typically taken at bedtime with a low-fat snack to allow flushing to occur during sleep. Nicotinamide can be taken at any time; morning dosing aligns with circadian NAD+ biology.

  • Half-life and pharmacokinetics: Immediate-release nicotinic acid has a 20–45 minute plasma half-life; extended-release formulations release over 8–12 hours. Nicotinamide has a 4-hour plasma half-life. Once-daily dosing is standard for extended-release nicotinic acid; nicotinamide is typically split twice daily.

  • Single vs. split dosing: Extended-release nicotinic acid is once-daily. Immediate-release nicotinic acid is often divided to reduce flushing intensity but can be once-daily at lower doses. Nicotinamide for skin-cancer chemoprevention is split into 500 mg twice daily per ONTRAC.

  • Genetic considerations: Variants in HCA2 may influence flushing intensity. MTHFR variants may modulate methylation of nicotinamide to 2PY/4PY and could affect both efficacy and the cardiovascular metabolite signal. Pharmacogenomic dose adjustment is not yet clinical standard.

  • Sex-based differences: Women may experience more pronounced flushing on nicotinic acid; otherwise, no clinically established sex-specific dosing exists.

  • Age-related considerations: Adults over 60 may benefit from starting at the low end given reduced renal and hepatic clearance and a higher risk of polypharmacy. The strongest skin-cancer chemoprevention signals come from older-adult cohorts.

  • Baseline biomarker levels: Adults with low HDL, high triglycerides, or elevated Lp(a) are most likely to derive lipid benefit. Adults with normal lipids generally do not need nicotinic acid.

  • Pre-existing health conditions: Adults with diabetes, gout, liver disease, or peptic ulcer disease should generally use nicotinamide rather than nicotinic acid when an NAD+ or skin application is the goal.

Discontinuation & Cycling

  • Long-term vs. short-term use: Niacin for skin-cancer chemoprevention or lipid modification is generally framed as long-term, since benefits reverse upon discontinuation (ONTRAC explicitly documented loss of skin-cancer benefit after stopping). Niacin for pellagra is short-term until symptoms resolve.

  • Withdrawal effects: No formal withdrawal syndrome has been documented. Lipid effects reverse over weeks; NAD+ levels return toward baseline over days to weeks.

  • Tapering protocol: Tapering is not strictly required but is reasonable for high-dose nicotinic acid (≥2 g/day) to avoid rebound flushing or vasoconstriction; reduce by 500 mg every 2 weeks.

  • Cycling: No clear evidence supports routine cycling. Some practitioners advocate periodic 4–6 week breaks from high-dose nicotinic acid to allow methylation reserves to recover, although direct human evidence for this practice is limited. Most clinical trials used continuous daily dosing.

  • Re-initiation: When restarting after a break, re-titrate from a low dose to mitigate flushing and gastrointestinal symptoms.

Sourcing and Quality

Sourcing, purity, and formulation are particularly important for niacin because the supplement market includes products with substantially different clinical profiles labeled under similar names.

  • Form selection: Distinguish among (1) immediate-release nicotinic acid (effective on lipids, flushing-prone), (2) prescription extended-release nicotinic acid (Niaspan; effective on lipids with reduced flushing and acceptable hepatotoxicity), (3) sustained-release nicotinic acid (over-the-counter “slow-release”; high hepatotoxicity risk and best avoided), (4) inositol hexanicotinate (“no-flush niacin”; minimal flushing but also minimal lipid effects), and (5) nicotinamide / niacinamide (no flushing, no lipid effects, used for skin and NAD+ applications).

  • Third-party testing: ConsumerLab notes that niacin/B3 products must contain at least 100% and no more than 125% of the labeled amount to pass independent verification. Products with published certificates of analysis (COA) and third-party seals are preferred.

  • GMP certification: Products manufactured in FDA-registered, GMP (Good Manufacturing Practice) certified facilities offer greater quality assurance than uncertified manufacturers.

  • Reputable brands: Pure Encapsulations, Thorne, Designs for Health, Jarrow Formulas, and Life Extension are commonly cited as reputable nicotinic-acid and nicotinamide producers in clinical practice. For prescription extended-release nicotinic acid, Niaspan (AbbVie) is the most extensively studied formulation.

  • Avoid sustained-release marketed as “slow release” or “time release”: These over-the-counter formulations have been repeatedly associated with hepatotoxicity and should be avoided in favor of immediate-release or prescription extended-release.

  • Stability and storage: Both nicotinic acid and nicotinamide are reasonably stable; store in a cool, dry place with the bottle tightly sealed.

  • Combination products: Many cardiovascular and “lipid support” supplements combine niacin with red yeast rice, plant sterols, or berberine. Evaluate combinations on the merits of each ingredient and ensure that total niacin equivalents are tracked.

Practical Considerations

  • Time to effect: Lipid effects of nicotinic acid emerge within 4 weeks and reach steady-state by 8–12 weeks. Skin-cancer chemoprevention with nicotinamide produces measurable reductions in actinic keratoses by 3 months and in skin-cancer counts by 12 months. Skin-quality effects of oral nicotinamide typically take 3–6 months.

  • Common pitfalls: Confusing the forms (taking nicotinamide for lipid effects, where it is inactive); using over-the-counter sustained-release nicotinic acid (high hepatotoxicity); using inositol hexanicotinate (“no-flush niacin”) expecting lipid benefits (minimal effect); discontinuing nicotinic acid for unbearable flushing without trying titration or aspirin pretreatment; failing to monitor liver enzymes and HbA1c on gram-level doses; combining with simvastatin at high doses (myopathy risk).

  • Regulatory status: Nicotinic acid and nicotinamide are widely available as dietary supplements in the US, EU, and most jurisdictions. Niaspan (extended-release nicotinic acid) is FDA-approved as a prescription drug for hyperlipidemia. Marketing claims for longevity or specific disease prevention are generally not approved by the FDA.

  • Cost and accessibility: Niacin is one of the least expensive supplements. A 30-day supply of immediate-release nicotinic acid (500 mg) or nicotinamide (500 mg) typically costs $5–$15 USD. Prescription extended-release nicotinic acid (Niaspan) is more expensive but generally insurance-covered for hyperlipidemia indications. Niacin is widely available from major retailers and pharmacies.

Interaction with Foundational Habits

  • Sleep: Direct, generally neutral. Nicotinic acid is commonly taken at bedtime to allow flushing to occur during sleep, but the flushing itself can fragment sleep in the first weeks of use. Nicotinamide has no known adverse sleep effects and is sometimes reported to improve sleep quality in subjective measures. Practical consideration: take nicotinic acid at bedtime with a low-fat snack; take nicotinamide in the morning if any sleep disturbance is observed.

  • Nutrition: Indirect, supportive. Niacin is endogenously synthesized from tryptophan, with about 60 mg tryptophan yielding 1 mg niacin equivalent. Adequate dietary protein (animal or legume), folate, B12, and choline support both endogenous niacin synthesis and the disposal pathways for high-dose supplemental niacin. Nicotinic acid taken on an empty stomach worsens flushing. Practical consideration: take niacin with food, particularly a low-fat snack, and ensure adequate methyl-donor nutrition.

  • Exercise: Indirect, generally neutral. Nicotinic acid’s inhibition of lipolysis can theoretically reduce free-fatty-acid availability during prolonged endurance exercise; this is rarely clinically meaningful at typical dosing. NAD+ replenishment supports mitochondrial function and may favor recovery, although direct evidence for plain niacin/nicotinamide on training adaptations is limited (most NAD+-precursor exercise data come from nicotinamide riboside). Practical consideration: take nicotinic acid in the evening rather than pre-workout to avoid flushing during exercise.

  • Stress management: Indirect, supportive. NAD+ supports the cellular stress response via SIRT1 (sirtuin 1, a NAD+-dependent enzyme regulating metabolism and stress response) and PARP activation, and chronic psychosocial stress depletes NAD+ via PARP-mediated DNA repair. Niacin and nicotinamide replenish NAD+ pools but do not specifically modulate cortisol (the body’s primary stress hormone). Practical consideration: niacin is not a substitute for sleep, social connection, or stress-management practices and is best layered on top of them.

Monitoring Protocol & Defining Success

Baseline laboratory testing is performed in clinical practice before initiating supplemental niacin to establish reference values, screen for contraindications (subclinical liver disease, glucose intolerance, gout, kidney impairment), and enable meaningful interpretation of subsequent measurements. The depth of monitoring scales with the form and dose: nicotinamide ≤1,000 mg/day requires minimal monitoring, while nicotinic acid at gram-level doses requires comprehensive serial labs.

Ongoing monitoring follows a cadence of repeat testing at 6–12 weeks after initiation or any dose increase, then every 6 months during chronic supplementation. Adults over 60 or with pre-existing metabolic, hepatic, or renal conditions may benefit from more frequent monitoring (every 3–6 months).

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Fasting lipid panel (TC, LDL, HDL, TG) TC <200; LDL <100; HDL >60; TG <100 mg/dL (functional) Tracks the principal lipid-modifying effects of nicotinic acid TC = total cholesterol; LDL = low-density lipoprotein; HDL = high-density lipoprotein; TG = triglycerides. Fasting for 12 hours recommended. Functional triglyceride target <100 vs. conventional <150 mg/dL.
Lipoprotein(a) <30 mg/dL or <75 nmol/L Tracks an independent atherosclerotic risk factor that nicotinic acid lowers by 20–30% Lp(a) = lipoprotein(a). Genetically determined; one-time measurement is generally sufficient unless on Lp(a)-lowering therapy.
Apolipoprotein B (ApoB) <80 mg/dL (functional) Counts atherogenic particles; tracked by Saboori et al., 2024 to fall on niacin ApoB = apolipoprotein B. Non-fasting acceptable; preferred over LDL-C alone for risk stratification.
ALT 7–35 U/L (functional: <25 U/L) Monitors for hepatocellular stress, particularly important on gram-level nicotinic acid ALT = alanine aminotransferase, a liver enzyme. Functional medicine targets ALT <25 U/L; conventional upper limit is 35–40 U/L.
AST 10–35 U/L (functional: <25 U/L) Monitors for hepatocellular stress; elevated alongside ALT suggests liver injury AST = aspartate aminotransferase. Can also rise after intense exercise; time blood draw >48 hours after strenuous activity.
Fasting glucose 72–85 mg/dL (functional) Tracks the glycemic impact of nicotinic acid Conventional normal is 70–99 mg/dL. 8–12 hour fast required.
HbA1c 4.8–5.2% (functional) Longer-term metabolic monitoring; key safety endpoint per HPS2-THRIVE HbA1c = glycated hemoglobin, a marker of long-term blood sugar control. Conventional “normal” is <5.7%; functional optimal is <5.2%. No fasting required.
Uric acid 3.5–6.0 mg/dL (women), 3.5–7.0 mg/dL (men) Tracks gout-flare risk on nicotinic acid Conventional upper limit is approximately 7.0 mg/dL. Random sample acceptable.
Creatinine / eGFR eGFR >90 mL/min/1.73m² Monitors kidney function eGFR = estimated glomerular filtration rate. Conventional “normal” is >60; functional range is >90.
hs-CRP <1.0 mg/L (functional) Tracks systemic inflammation, the domain in which niacin’s anti-inflammatory effect is most measurable hs-CRP = high-sensitivity C-reactive protein, a general marker of systemic inflammation. Avoid testing during acute illness which transiently elevates hs-CRP.
Homocysteine 5–8 µmol/L (functional) Screens for methylation status, relevant given niacin’s methyl-group consumption at higher doses Conventional upper limit is 15 µmol/L; functional medicine prefers <8. Fasting preferred.

Qualitative markers to track:

  • Flushing intensity and duration (declining over 4–8 weeks)
  • Energy levels and sustained activity tolerance
  • Sleep quality (time to fall asleep, awakenings, restorative sleep)
  • Skin quality, redness, and pigmentation
  • Number of new actinic keratoses or skin cancers (for chemoprevention indications)
  • Gout-symptom recurrence
  • Gastrointestinal tolerance
  • Overall sense of vitality and well-being

Emerging Research

Several active clinical trials and emerging research directions are likely to advance the understanding of niacin and nicotinamide over the next several years.

  • Phase 3 nicotinamide for open-angle glaucoma (NAMinG): 496-participant Phase 3 trial of oral nicotinamide for open-angle glaucoma neuroprotection (NCT05405868), the most definitive ongoing evaluation of nicotinamide as a glaucoma therapy.

  • Comparison of NAD+ precursors in glaucoma: 138-participant Phase 2 trial directly comparing nicotinamide riboside, nicotinamide, nicotinamide mononucleotide, and nicotinic acid for retinal ganglion cell preservation (NCT06991712).

  • Glaucoma Nicotinamide Trial: 660-participant trial of high-dose oral nicotinamide as an add-on to standard glaucoma therapy (NCT05275738).

  • Nicotinamide and Pyruvate for Open Angle Glaucoma: 250-participant Phase 2/3 RCT combining nicotinamide with pyruvate (NCT05695027).

  • Nicotinamide chemoprevention in transplant recipients: 396-participant Phase 3 trial of nicotinamide for keratinocyte carcinoma prevention in solid organ transplant recipients (NCT05955924), addressing the population in which the Tosti et al. meta-analysis found no overall benefit.

  • Nicotinamide in chronic lymphocytic leukemia patients with prior skin cancer: 86-participant Phase 2 trial in a high-risk immunosuppressed population (NCT04844528).

  • Controlled-ileal-release nicotinic acid for prediabetes (CONCEPT): 390-participant Phase 2 trial of a microbiome-targeted nicotinic acid formulation designed to act locally in the ileum and avoid systemic 2PY/4PY exposure (NCT07286747).

  • High-dose nicotinamide for major adverse kidney events in septic shock: 310-participant Phase 3 trial (NCT04589546).

  • Mechanistic 4PY translational research: Continued work on whether the Ferrell et al., 2024 signal extends to typical supplemental doses of nicotinic acid and nicotinamide will be central to defining the long-term cardiovascular safety boundary.

  • Counter-evidence in dermatology cohorts: Real-world cohort data such as the Salem et al., 2026 TriNetX study reporting reduced major cardiovascular events in nicotinamide users, and the Breglio et al., 2025 VA cohort on chemoprevention efficacy, are likely to be re-examined and replicated as the 4PY pathway is further characterized.

  • Niacin and infectious-disease modulation: A 2025 meta-analysis (Curran et al., 2025) of niacin and NAD-metabolite treatment in animal infection models suggests benefit and motivates evaluation in clinically relevant human contexts.

Conclusion

Niacin is a vitamin with two supplemental forms — nicotinic acid and nicotinamide — that share a common biochemical destination but produce strikingly different clinical profiles. Nicotinic acid is one of the few oral options that meaningfully lowers an inherited atherogenic blood-fat marker, reduces triglycerides, and raises good cholesterol, and remains relevant for adults with adverse lipid profiles who lack access to newer injectable therapies. Nicotinamide, by contrast, drives skin-quality and skin-cancer chemoprevention and is being tested for glaucoma neuroprotection.

The cardiovascular question is the central tension in the contemporary literature. Original pre-statin trials showed real benefit, including long-term mortality reduction. Modern trials adding niacin to optimized statin therapy have not shown additional benefit, and identification of a breakdown product that promotes vascular inflammation offers a plausible mechanistic explanation. At the same time, real-world dermatology cohort data have shown reduced cardiovascular events among nicotinamide users, leaving the picture unsettled.

Both forms carry well-documented side effects — flushing and metabolic effects for nicotinic acid; dose-dependent liver, gastrointestinal, and theoretical methylation effects for both — that scale with dose and duration. The pivotal modern trials were sponsored by manufacturers of the patented formulations under test, and the downgraded guideline status of inexpensive generic niacin aligns with payer and manufacturer incentives favoring higher-margin patented therapies — a structural-bias consideration belonging alongside the trial evidence. For a longevity-oriented adult, niacin is best understood as a targeted intervention chosen for a specific lipid, dermatologic, or cellular-metabolism goal, matched in form, dose, and duration.

Top - Benefits - Risks - Protocol